Related references
Note: Only part of the references are listed.Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the fas pathway in the metastatic process of osteosarcoma
Nadezhda V. Koshkina et al.
MOLECULAR CANCER RESEARCH (2007)
Estrogen sulfotransferase (SULT1E1) expression in benign and malignant human bone tumors
Martin Svoboda et al.
JOURNAL OF SURGICAL ONCOLOGY (2007)
Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma
Armelle Orosco et al.
CANCER RESEARCH (2007)
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
M. Bilban et al.
LEUKEMIA (2006)
Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interieukin-1β
T Kalinski et al.
CANCER (2006)
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy - 15-year experience in 789 patients treated at a single institution
G Bacci et al.
CANCER (2006)
Clinico-histologic parameters of osteosarcoma patients with late relapse
EI Hauben et al.
EUROPEAN JOURNAL OF CANCER (2006)
Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms V0 and V1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells
D Nikitovic et al.
IUBMB LIFE (2006)
Clinical relevance of Fas expression in oesophageal squamous cell carcinoma
KW Chan et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Discovering statistically significant pathways in expression profiling studies
L Tian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Syndecan-2 overexpression induces osteosarcoma cell apoptosis:: Implication of syndecan-2 cytoplasmic domain and JNK signaling
D Modrowski et al.
BONE (2005)
Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes
S Mendoza et al.
CANCER GENETICS AND CYTOGENETICS (2005)
An expression signature classifies chemotherapy-resistant pediatric osteosarcoma
MB Mintz et al.
CANCER RESEARCH (2005)
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway
BH Hoang et al.
CANCER RESEARCH (2004)
Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts
M Bilban et al.
JOURNAL OF CELL SCIENCE (2004)
Angiopoietins in tumours: the angiogenic switch
CR Tait et al.
JOURNAL OF PATHOLOGY (2004)
Neoadjuvant chemotherapy for osteosarcoma of the extremity - Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome
G Bacci et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma
EI Hauben et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2003)
Identification of drug-regulated genes in osteosarcoma cells
J Fellenberg et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
FGFs, their receptors, and human limb malformations: Clinical and molecular correlations
AOM Wilkie et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Decorin suppresses tumor cell-mediated angiogenesis
DS Grant et al.
ONCOGENE (2002)
Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup
EI Hauben et al.
EUROPEAN JOURNAL OF CANCER (2002)
Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute
S Ferrari et al.
ANNALS OF ONCOLOGY (2001)
Proteins expressed in osteosarcoma and serum levels as prognostic factors
K Trieb et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
Share Paper
